As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of PDS Biotechnology Corporation. The largest reported stake is Nant Capital, LLC's, at 19.9%. 2 filings are on record since August 14, 2025 (Schedule 13D, September 21, 2026).
Sell to companies like PDS Biotechnology Corporation? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
PDS Biotechnology Corporation has 2 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, par value $0.00033 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-08-25 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Nant Capital, LLC | 19.9% | 20,336,335 | SCHEDULE 13D, 2026-09-21 | 2026-09-14 |
| Armistice Capital, LLC | 4.99% | 2,283,288 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind PDS Biotechnology Corporation and the warning signs.
Free to see. No signup.
Keep reading
More on PDS Biotechnology Corporation and the records around it.
PDS Biotechnology Corporation elsewhere on the record
- Leadership changes Sep 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch PDS Biotechnology Corporation
Get an email when PDS Biotechnology Corporation files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PDS Biotechnology Corporation?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PDS Biotechnology Corporation: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PDS Biotechnology Corporation covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nant Capital, LLC | 20,336,335 | 0 | 20,336,335 | 0 | SCHEDULE 13D, 2026-09-21 |
| Patrick Soon-Shiong | 20,336,335 | 0 | 20,336,335 | 0 | SCHEDULE 13D, 2026-09-21 |
The latest filing identifies PDS Biotechnology Corporation by CUSIP 70465T107 and gives its principal executive office as 303A College Road East, Princeton, NJ 08540 (SCHEDULE 13D, 2026-09-21).
Purpose of Transaction (Item 4)
Nant Capital, LLC
The information set forth in Item 3 of this Schedule is incorporated herein by reference. The Reporting Person acquired their shares of Common Stock, Pre-Funded Warrants and Common Warrants as an investment in the ordinary course of business. At the Milestone Closing, which will be triggered by the Issuer's submission of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with Nant Capital to the U.S. Food & Drug Administration (the "Milestone Event"), Nant Capital, along with certain other PIPE Investors, will be obligated to purchase and the Issuer will be obligated to issue to Nant Capital shares of Comon Stock or Pre-Funded Warrants in lieu thereof for an aggregate subscription amount of $10,000,000. The purchase price per share of Common Stock at the Milestone Closing is equal to $0.22, subject to adjustment for stock splits, stock dividends, stock combinations and similar transactions. The purchase price per Pre-Funded Warrant is equal to $0.21967. The Milestone Closing will occur no later than the fifth (5th) business day after the Milestone Event. The number of securities purchase by Nant Capital in the Milestone Closing will be subject to a 19.9% beneficial ownership limitation. On September 14, 2026, the Reporting Person, who is the sole member of Nant Capital, and James Banaag, the Senior Vice President Finance, Corporate Strategy of NantWorks, LLC ("NantWorks"), an affiliate of the Reporting Person, were each appointed to the …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-21; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-09-21 | Nant Capital, LLC | 19.9% | SCHEDULE 13D |
Questions about who owns PDS Biotechnology Corporation
Who owns PDS Biotechnology Corporation?
On this page, one holder's latest ownership filing reports 5% or more of PDS Biotechnology Corporation: Nant Capital, LLC (19.9%, Schedule 13D, filed 2026-09-21).
When did Nant Capital, LLC buy into PDS Biotechnology Corporation?
The filings give report dates, not purchase dates. The earliest filing from Nant Capital, LLC on this page is the Schedule 13D, filed 2026-09-21, reporting 19.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for PDS Biotechnology Corporation
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 20, 2026 | Leadership change: Deborah A. Ramsdell appointed, Director | — | Leadership changes | Source |
| September 14, 2026 | Leadership change: James Banaag appointed, Director | — | Leadership changes | Source |
| August 25, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 19, 2026 | Leadership change: Janetta Trochimiuk appointed, President and Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for PDS Biotechnology Corporation. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.